TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01599364
Drug: Atazanavir, ritonavir, lamivudine
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
Study: NCT01890629
Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04497961
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
Study: NCT00740805
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02981628
Drug: Asparaginase Erwinia chrysanthemi
Normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Asparaginase Erwinia chrysanthemi
Study: NCT02508649
Drug: selepressin
Normalized name: Selepressin
DrugBank: Selepressin (DB12495)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00444665
Drug: Travatan-Z
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03751124
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relugolix 40 mg tablet administered orally once daily
Study: NCT02981628
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02981628
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or SC
Study: NCT02981628
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or IM
Study: NCT02981628
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03751124
Drug: Placebo for relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
Study: NCT00446134
Drug: Taribavirin
Normalized name: Taribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Study: NCT00446134
Drug: Taribavirin
Normalized name: Taribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Study: NCT00446134
Drug: Taribavirin
Normalized name: Taribavirin
DrugBank: Taribavirin (DB06408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Study: NCT00446134
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Study: NCT02792088
Drug: Besifovir 150mg
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study: NCT02792088
Drug: Tenofovir 300mg
Normalized name: EMTRICITABINE 200MG/TENOFOVIR 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study: NCT02149199
Drug: terbutaline 'as needed' + placebo budesonide bid
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Study: NCT01246908
Drug: CX157 (TriRima)
Normalized name: CX157
DrugBank: CX157 (DB05205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Study: NCT02173262
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02173262
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02683746
Drug: Lyophilized albiglutide DCC pen injector
Normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
Study: NCT02683746
Drug: Lyophilized albiglutide DCC pen injector matching placebo
Normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
Study: NCT02683746
Drug: Albiglutide liquid auto-injector
Normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Study: NCT02683746
Drug: Albiglutide liquid auto-injector matching placebo
Normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Study: NCT01191216
Drug: 1-methyl-d-tryptophan
Normalized name: 1-methyl-D-tryptophan
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01191216
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401362
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 1
Study: NCT00401362
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 2
Study: NCT02047318
Drug: LUM001 (Maralixibat)
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
Study: NCT00924781
Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Study: NCT00924781
Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Study: NCT00689442
Drug: JTT-705 600 mg and atorvastatin 20 mg
Normalized name: atorvastatin and amlodipine
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments
Study: NCT00689442
Drug: Placebo and atorvastatin 20 mg
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study: NCT01097083
Drug: Coriolus Versicolor
Normalized name: TRAMETES VERSICOLOR
DrugBank: Trametes versicolor fruiting body (DB14287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01073371
Drug: Prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
Study: NCT02208778
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 54 participants will be allocated for duloxetine treatment
Study: NCT00865423
Drug: Gabapentin 800 mg Tablets, single dose
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT00100334
Drug: PPI-1019 (APAN)
Normalized name: PPI-1019
DrugBank: PPI-1019 (DB05832)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566695
Drug: Oral Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg daily, days 1 to 21 of each 28-day treatment cycle
Study: NCT01104532
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral tablet
Study: NCT00370045
Drug: Bivalirudin with and without eptifibatide
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00390026
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00390026
Drug: Verteporfin photodynamic therapy (PDT)
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02815280
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle foam applied topically once daily for 12 weeks
Study: NCT00040846
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02174549
Drug: Tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection into the tumor feeding artery
Study: NCT00040846
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00040846
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT03594175
Drug: CUSA-081
Normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
Study: NCT03594175
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
Study: NCT03513445
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study: NCT03513445
Drug: naropin
Normalized name: Naropin
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study: NCT01230177
Drug: etanercept (genetical recombination)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
Study: NCT01534182
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mg orally once a day
Study: NCT01534182
Drug: Interferon beta - 1a (IFN)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 44 mcg subcutaneously three times a week
Study: NCT01534182
Drug: Glatiramer acetate (GA)
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg subcutaneously once a day
Study: NCT01479283
Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.
Study: NCT01479283
Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.
Study: NCT03313661
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
Study: NCT03313661
Drug: Gliclazide
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gliclazide (60-120 mg)
Study: NCT00770146
Drug: Mipomersen sodium
Normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/mL
Study: NCT00003798
Drug: motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03413722
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient's physician will prescribe drug according to standard practice.
Study: NCT03413722
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient's physician will prescribe drug according to standard practice.
Study: NCT03620201
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03800550
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bedaquiline tablet will be administered, orally.
Study: NCT04155541
Drug: dacomitinib hydrate
Normalized name: dacomitinib anhydrous
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
Study: NCT03203746
Drug: Lycopene + SRP
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01864356
Drug: NT100
Normalized name: POMEGRANATE 250 mg / EUCOMMIA ULMOIDES BARK 200 mg / ACHYRANTHES JAPONICA ROOT 50 mg ORAL TABLET [HL Joint100 for Joint and Cartilage]
DrugBank: Eucommia ulmoides bark (DB14259)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04111978
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitor
Study: NCT02195011
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Study: NCT00674154
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2800 IE daily in 52 weeks
Study: NCT03494816
Drug: Axitinib Oral Tablet
Normalized name: axitinib Oral Tablet
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Study: NCT02250833
Drug: CKD-828
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Study: NCT02250833
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
Study: NCT02250833
Drug: S-amlodipine
Normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
Study: NCT02775240
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose
Study: NCT02775240
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200mg twice a day for 8 days
Study: NCT02775240
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg oral dose
Study: NCT01203852
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.
Study: NCT02756988
Drug: Coppertone (BAY987704)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
Study: NCT00600145
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
Study: NCT01433276
Drug: Hyperosmolar sodium lactate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
Study: NCT01991184
Drug: GDC-0853
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple escalating doses
Study: NCT01613170
Drug: Toviaz
Normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toviaz 4mg daily
Study: NCT01613170
Drug: Premarin
Normalized name: Premarin
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin cream 1 g per vagina twice weekly